- Human pathology

Home > G. Tumoral pathology > Molecular pathology of tumors > Genetic anomalies > Mutation testing > Cancer mutations > KRAS-G12C



Monday 1 July 2013

p.Gly12Cys c.34G>T



The G12C KRAS mutation is a strong negative predictor for EGFR-TKI treatment, whereas other KRAS mutation types have not negatively predicted treatment efficacy compared with that for the wild-type KRAS genotype. (23313110)


- The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Fiala O, Pesek M, Finek J, Benesova L, Belsanova B, Minarik M. Cancer Genet. 2013 Jan-Feb;206(1-2):26-31. doi : 10.1016/j.cancergen.2012.12.003 PMID: 23313110